ArticleWorld journal of gastroenterology2012
Cost-benefit analysis of esophageal cancer endoscopic screening in high-risk areas of China.
Article in World journal of gastroenterology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Profiles and Findings of Population-Based Esophageal Cancer Screening With Endoscopy in China: Systematic Review and Meta-analysis.JMIR public health and surveillance · 2023Pooled it
- Quality of Health Economic Evaluations in Mainland China: A Comparison of Peer-Reviewed Articles in Chinese and in English.Applied health economics and health policy · 2022Pooled it
- Opening the black box: defining true-negative outcomes in esophageal cancer screening - a population-based study.BMC medicine · 2025Trial
- Endoscopy screening effect on stage distributions of esophageal cancer: A cluster randomized cohort study in China.Cancer science · 2018Trial
- Early detection of gastrointestinal cancers in low- and middle-income countries: A risk-stratified framework and implementation roadmap.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Review
- Article
- Cost-utility of endoscopic screening strategies for upper gastrointestinal cancer across China: a modeling study.Frontiers in public health · 2025Article
- Predicting the potential deterioration of Barrett's esophagus based on gut microbiota: a Mendelian randomization analysis.Mammalian genome : official journal of the International Mammalian Genome Society · 2024Article
- Improving esophageal cancer screening across the globe: Translating knowledge into action.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2024Review
- Esophageal cancer screening, early detection and treatment: Current insights and future directions.World journal of gastrointestinal oncology · 2024Review
- Long-term esophageal cancer risk and distinct surveillance intervals after a single endoscopy screening: a multicentre population-based cohort study.EClinicalMedicine · 2023Article
- Public Preference Heterogeneity and Predicted Uptake Rate of Upper Gastrointestinal Cancer Screening Programs in Rural China: Discrete Choice Experiments and Latent Class Analysis.JMIR public health and surveillance · 2023Article
- Optimal starting age of endoscopic screening for esophageal cancer in China: A multicenter prospective cohort study.Cancer medicine · 2023Article
- Endoscopic Management of Esophageal Cancer.Cancers · 2022Review
- Long-term results of an endoscopic screening program for superficial esophageal cancer in patients with head and neck squamous cell carcinoma.Endoscopy international open · 2022Article
- Economic Burden Conferred by Population-Level Cancer Screening on Resource-Limited Communities: Lessons From the ESECC Trial.Frontiers in oncology · 2022Article
- Esophageal cancer: Epidemiology, risk factors and screening.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2021Article
- Estimated Cost-effectiveness of Endoscopic Screening for Upper Gastrointestinal Tract Cancer in High-Risk Areas in China.JAMA network open · 2021Article
- Cost-effectiveness analysis of camrelizumab in the second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.Annals of translational medicine · 2021Article
- Global Burden, Risk Factors, and Trends of Esophageal Cancer: An Analysis of Cancer Registries from 48 Countries.Cancers · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo estimate the cost-benefit of endoscopic screening strategies of esophageal cancer (EC) in high-risk areas of China.
methodsMarkov model-based analyses were conducted to compare the net present values (NPVs) and the benefit-cost ratios (BCRs) of 12 EC endoscopic screening strategies. Strategies varied according to the targeted screening age, screening frequencies, and follow-up intervals. Model parameters were collected from population-based studies in China, published literatures, and surveillance data.
resultsCompared with non-screening outcomes, all strategies with hypothetical 100,000 subjects saved life years. Among five dominant strategies determined by the incremental cost-effectiveness analysis, screening once at age 50 years incurred the lowest NPV (international dollar-I$55 million) and BCR (2.52). Screening six times between 40-70 years at a 5-year interval [i.e., six times(40)f-strategy] yielded the highest NPV (I$99 million) and BCR (3.06). Compared with six times(40)f-strategy, screening thrice between 40-70 years at a 10-year interval resulted in relatively lower NPV, but the same BCR.
conclusionEC endoscopic screening is cost-beneficial in high-risk areas of China. Policy-makers should consider the cost-benefit, population acceptance, and local economic status when choosing suitable screening strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.